NASH drugs come into focus as field awaits late-stage data

For drugmakers searching to find a treatment for non-alcoholic steatohepatitis, a chronic liver condition commonly known as NASH, questions still outnumber answers.

What's become clear, however, is that a therapeutic solution will require several complementary approaches, rather than a single cure-all drug.